Key Highlights

  • DoorDash (NASDAQ:DASH) fell 6.10% on October 26, 2026 after a media report that it is in talks to buy Instacart's parent, whose shares rose 7.87%, though neither company had confirmed the report.
  • Howard Hughes Holdings (NYSE:HHH) will join the S&P SmallCap 600 before the open on Wednesday, October 28, 2026, replacing Arcosa, and its shares rose 4.72% in premarket trading on October 26.
  • Eledon Pharmaceuticals (NASDAQ:ELDN) faces a short seller report dated October 23 that claims it is cash-strapped ahead of a 620-patient Phase 3, and these allegations have not been confirmed or checked here.
  • Genmab (NASDAQ:GMAB) jumped 12% in European trading on October 26 on a positive late-stage trial update, while the US-listed receipt move, the trial name and the results were not available in published market data.

DoorDash (NASDAQ:DASH): Takeover Talk Hits the Buyer

On Monday, October 26, 2026, a media report said that DoorDash (NASDAQ:DASH) is in talks to acquire the company that operates the Instacart grocery delivery platform, and that a deal could be agreed this week. DoorDash shares fell 6.10%, and shares of Maplebear (NASDAQ:CART) rose 7.87%, in published market data. Neither company had confirmed the report when this article was written. The terms, including price per share, the form of payment and any premium, were not reported. Until the companies make an announcement or file a document with the SEC, the talks remain a report and not a fact, and talks of this kind often end without a deal. A denial, a delay or a change in structure are all possible outcomes. A target's shares rise because shareholders expect to be paid more than the current price. A buyer's shares often fall because it may pay a premium, issue shares or use cash, and because it takes on the task of combining two businesses. DoorDash operates restaurant and retail delivery, and Instacart specializes in grocery orders from supermarkets, so a combination would widen DoorDash's grocery reach. Overlap between the two services would likely draw attention from antitrust regulators, who could ask for information, delay approval or require changes.

Howard Hughes Holdings (NYSE:HHH): S&P SmallCap 600 Entry

On October 26, 2026, S&P Dow Jones Indices announced, as reported, that Howard Hughes Holdings (NYSE:HHH) will join the S&P SmallCap 600 before the open on Wednesday, October 28, replacing Arcosa. The shares rose 4.72% in premarket trading that day. An index inclusion means the company becomes part of a benchmark that thousands of passive funds track. Those funds must hold each constituent in proportion to its weight, so they buy shares on or before the effective date. The announcement gave investors a few sessions to position, which often leads to a price rise before the change takes effect and sometimes to a reversal afterward. Passive funds do not choose stocks on merit. The amount they buy depends on the company's weight in the index and on how many shares are available to trade, so a smaller free float can mean a larger price effect. Arcosa (NYSE:ACA) leaves the index in the swap, and funds will sell it. Studies of index changes show that the effect on price is often largest between the announcement and the effective date and can fade afterward.

Eledon Pharmaceuticals (NASDAQ:ELDN): Short Seller Report

A short seller published a report on October 23, 2026, and its claims were still being discussed on October 26. According to the report, Eledon Pharmaceuticals (NASDAQ:ELDN) lacks enough cash to fund a 620-patient Phase 3 trial and will need to sell equity within 60 to 90 days. The report cites going-concern language and an at-the-market facility of USD 75 million. These are allegations. The company's response and its latest cash balance were not available for this article, and the claims were not independently checked. A reader should check the cash figure, the quarterly burn rate and the facility terms in the company's SEC filings. Cash runway is the number of months a company can operate before it needs funding, and it is the central test of the allegation. Going-concern language is a statement in a company's financial statements that management or auditors see substantial doubt about its ability to continue operating for at least twelve months without new funding. An at-the-market facility lets a company sell shares gradually into the open market through a broker, at prevailing prices, up to a stated amount. Each sale adds shares and dilutes existing holders, so a stock can fall even when a trial goes well. A USD 75 million facility gives flexibility but also means that new shares can reach the market without a fixed announcement date.

Genmab (NASDAQ:GMAB): Trial Update Lifts Shares

Genmab, a biotechnology company based in Denmark, saw its shares rise 12% in European trading on Monday, October 26, 2026 after a positive update from a late-stage trial, according to published market data. A late-stage trial, usually Phase 3, tests a treatment in a large group of patients and is the last major step before regulatory submission. The information available for this article did not name the trial or give the results, such as survival or response rates, so no clinical figure is stated here. Genmab (NASDAQ:GMAB) trades in the United States as an American depositary receipt, and the US move was not available. The company is known for antibody-based cancer medicines and partnerships with larger drug makers. An American depositary receipt is a certificate that represents shares of a foreign company and trades on a US exchange in dollars. If the news came after the European close or before the US open, the US shares could react differently. Biotech investors usually look at the primary endpoint, safety, the comparison group and the timing of regulatory filings. The headline number is often only part of the story, so analysts read the full data once they are published.

Where Things Stand

The answer is that four different events moved the stocks: a reported takeover, an index change, a short seller report and a trial update. DoorDash (NASDAQ:DASH) and Eledon Pharmaceuticals involve unconfirmed claims, Howard Hughes Holdings has an announced index change and Genmab has positive but incomplete trial news. The next tests are confirmations, the October 28, 2026 index date and the full trial data. Next filings from DoorDash (NASDAQ:DASH) will add detail. Fresh disclosure from Howard Hughes Holdings (NYSE:HHH) is the next test. Official notices from Eledon Pharmaceuticals (NASDAQ:ELDN) remain the best guide. Further company updates from Genmab (NASDAQ:GMAB) are awaited. Further disclosure from Eledon Pharmaceuticals (NASDAQ:ELDN) would clarify the picture. Official notices from Genmab (NASDAQ:GMAB) remain the best guide.